Cargando…

Differentiating biochemical from clinical heparin resistance in COVID-19

Detalles Bibliográficos
Autores principales:	Lisman, Ton, Thachil, Jecko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471526/ https://www.ncbi.nlm.nih.gov/pubmed/32880796 http://dx.doi.org/10.1007/s11239-020-02259-5

Ejemplares similares

Heparin – Messias or Verschlimmbesserung?
por: Swan, Dawn, et al.
Publicado: (2021)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

The implications of aspirin resistance in renal failure
por: Thachil, Jecko
Publicado: (2008)

The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017)

Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
por: Nielsen, Nathan D., et al.
Publicado: (2022)

DOACs and “newer” hemophilia therapies in COVID‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Lessons learnt from COVID‐19 coagulopathy
por: Thachil, Jecko
Publicado: (2021)

Usefulness of Combining D-Dimers with Thromboelastography
por: Thachil, Jecko
Publicado: (2020)

The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
por: Thachil, Jecko
Publicado: (2008)

The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease
por: Lisman, Ton, et al.
Publicado: (2021)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

A proposal for staging COVID‐19 coagulopathy
por: Thachil, Jecko, et al.
Publicado: (2020)

The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
por: May, Jori E., et al.
Publicado: (2020)

Heparin-induced hyponatremia in COVID-19: A latent culprit!
por: Panda, Rajesh, et al.
Publicado: (2021)

Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak
por: Lucatelli, Pierleone, et al.
Publicado: (2020)

Response to The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
por: Riker, Richard R., et al.
Publicado: (2020)

Management of heparin resistance in an emergency cardiac surgical patient
por: Isil, Canan Tulay, et al.
Publicado: (2012)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
por: Savioli, Felicio, et al.
Publicado: (2022)

Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?
por: Ahmed, Sakir, et al.
Publicado: (2020)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Heparin resistance during pediatric cardiac surgery: An unanticipated challenge for an anesthesiologist
por: Akhtar, Mohammad Irfan, et al.
Publicado: (2016)

Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020)

Abnormal coagulation tests before kidney biopsies—what next?
por: Thachil, Jecko
Publicado: (2013)

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19()
por: Huang, Ching-Tai, et al.
Publicado: (2020)

Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients
por: Preti, Paola S., et al.
Publicado: (2021)

Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin
por: Hosseini, Amin, et al.
Publicado: (2020)

Approach to post-COVID-19 syndrome (PC19S): How long to maintain corticotherapy and heparin after discharge from intensive care?
por: López Castro, José
Publicado: (2021)

Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation
por: Mazzitelli, Maria, et al.
Publicado: (2020)

Overt and non-overt disseminated intravascular coagulation and the potential role of heparin in the COVID-19 pandemic outbreak
por: Salamanna, Francesca, et al.
Publicado: (2020)

Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis
por: Abdel-Maboud, Mohamed, et al.
Publicado: (2020)

The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients
por: Calabretta, F., et al.
Publicado: (2022)

Nebulized Heparin to Reduce COVID-19-induced Acute Lung Injury: A Prospective Observational Study
por: Gupta, Bhavna, et al.
Publicado: (2023)

Heparin induced thrombocytopenia-type 2
por: Majeed, Tanveer A.
Publicado: (2010)

Refractory hyperkalemia related to heparin abuse
por: Bawaskar, Himmatrao S., et al.
Publicado: (2014)

Heparin-induced bullous hemorrhagic dermatosis()
por: Hamdi, Douja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fjoansuc0gn9e5n2546b6uugbi